Rethinking the impact of breast and prostate cancer screening. Part 2: The comment

[i]Note: the first part of this Commentary, The evidence, was issued on January 4, 2010.[/i]

Author(s)

• Anne Gompel
  Unité de Gynécologie-Endocrinienne, APHP, Hôtel-Dieu Hospital and University Paris Descartes, France

Citations

1. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587. doi: 10.1136/bmj.b2587. Published July 9, 2009.
   http://www.ncbi.nlm.nih.gov/pubmed/19589821
2. Esserman L, Shie Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:168592. Published October 21, 2009.
   http://www.ncbi.nlm.nih.gov/pubmed/19843904
3. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009;101:38498.
   http://www.ncbi.nlm.nih.gov/pubmed/19276457